166-180 of 344
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
MinuteCE®Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
MinuteCE®Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Sapna Patel, MD
John M. Kirkwood, MD
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Hussein Tawbi, MD, PhD
Paolo A. Ascierto, MD
ADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
CME/CEADCs Across the Spectrum of HER2 Expression in Metastatic Breast Cancer
Reshma L. Mahtani, DO
- advertisement
Ghayas Issa, MD
Amir Fathi, MD
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
CME/CECommunity Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Robert J. Motzer, MD
Elizabeth R. Plimack, MD, MS, FASCO
Ghayas Issa, MD
Amir Fathi, MD
Molecular Profiling as a Cornerstone of Precision AML Therapy
MinuteCE®Molecular Profiling as a Cornerstone of Precision AML Therapy
Ghayas Issa, MD
Amir Fathi, MD
Menin Inhibitors: Biologic and Clinical Rationale
MinuteCE®Menin Inhibitors: Biologic and Clinical Rationale
Ghayas Issa, MD
Amir Fathi, MD
Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
MinuteCE®Clinical Evidence on Monotherapy With Menin Inhibitors in R/R AML
Ghayas Issa, MD
Amir Fathi, MD
- advertisement
Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
MinuteCE®Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
Ghayas Issa, MD
Amir Fathi, MD
Managing Adverse Events Associated With Menin Inhibitors
MinuteCE®Managing Adverse Events Associated With Menin Inhibitors
Ghayas Issa, MD
Amir Fathi, MD
Ghayas Issa, MD
Amir Fathi, MD
